Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NQO2 | P16083 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | MAX | P61244 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18661294 | 0.80 | MAPT (0.43) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL13058525 | 0.78 | MAPT (0.42) | MAPTALDH1A1GAAKMT2ANPSR1 | |
| SCHEMBL29187248 | 0.76 | ADORA2A (0.37) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL29450004 | 0.75 | MAPT (0.62) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL382385 | 0.75 | MAPT (0.62) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL11038905 | 0.75 | MAPT (0.62) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL29589829 | 0.74 | TDP1 (0.58) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL19535296 | 0.74 | TDP1 (0.58) | MAPTALDH1A1POLBGAAKMT2A | |
| SCHEMBL14993411 | 0.74 | CYP1A2 (0.45) | MAPTALDH1A1POLBGAARAB9A | |
| SCHEMBL24924711 | 0.71 | CYP1A2 (0.35) | MAPTALDH1A1GAAKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095230-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2020-03-26 | — | — | US | disclosed |
| US-10442792-B2 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442792-B2 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2019-03-21 | — | — | US | disclosed |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2019-03-21 | — | — | US | disclosed |
| US-10077256-B2 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442792-B2 | Synthetic route to anti-viral agents | ACE, ACE2, PREP | MAPT 2781/4885ALDH1A1 4400/4885POLB 200/4885 |
| US-10077256-B2 | Synthetic route to anti-viral agents | ACE, ACE2, PREP | MAPT 2781/4885ALDH1A1 4400/4885POLB 200/4885 |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | MAPT 2781/4885ALDH1A1 4400/4885POLB 200/4885 |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | MAPT 2781/4885ALDH1A1 4400/4885POLB 200/4885 |
| US-20200095230-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | MAPT 2781/4885ALDH1A1 4400/4885POLB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.